noteworthy:
"The Company expects to generate near term revenues from the sales of cannabis oils, which will be available for patients through physicians authorised to prescribe medicinal cannabis under Special Access Category B."
......and.....
"In addition, the licence and related research trials enable Bod to develop cannabis based products and materials for potential export markets in Asia as part of a broader distribution strategy."
